Pfizer (PFE) Beats Stock Market Upswing: What Investors Need to Know

Core Viewpoint - Pfizer's upcoming earnings report is anticipated to show a significant decline in earnings and revenue compared to the previous year, raising investor interest [2][3]. Group 1: Stock Performance - Pfizer's stock increased by 1.16% to $24.51, outperforming the S&P 500's daily gain of 0.53% [1]. - Over the past month, Pfizer's stock has risen by 0.33%, which is below the Medical sector's gain of 2.87% and the S&P 500's gain of 0.71% [1]. Group 2: Earnings Estimates - Analysts expect Pfizer to report earnings of $0.68 per share on November 4, 2025, reflecting a year-over-year decline of 35.85% [2]. - The Zacks Consensus Estimate for Pfizer's revenue is projected at $16.81 billion, down 5.06% from the previous year [2]. Group 3: Full Year Projections - For the full year, the Zacks Consensus Estimates project earnings of $3.07 per share and revenue of $63.4 billion, indicating changes of -1.29% and -0.36% respectively from the prior year [3]. Group 4: Analyst Revisions and Rankings - Recent changes to analyst estimates for Pfizer are crucial as they reflect short-term business trends, with positive revisions indicating analyst optimism [3][4]. - Pfizer currently holds a Zacks Rank of 3 (Hold), with a 1.87% decline in the Zacks Consensus EPS estimate over the past month [5]. Group 5: Valuation Metrics - Pfizer's Forward P/E ratio is 7.88, significantly lower than the industry average of 14.5, suggesting it is trading at a discount [6]. - The PEG ratio for Pfizer is 0.8, compared to the industry average of 1.59, indicating a favorable valuation relative to expected earnings growth [6]. Group 6: Industry Context - The Large Cap Pharmaceuticals industry, part of the Medical sector, has a Zacks Industry Rank of 94, placing it in the top 39% of over 250 industries [7]. - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7].